Receptor-interacting protein kinase (RIPK)-1 is involved in RIPK3-dependent and -independent signaling pathways leading to cell death and/or inflammation. Genetic ablation of ripk1 causes postnatal lethality, which was not prevented by deletion of ripk3, caspase-8, or fadd. However, animals that lack RIPK1, RIPK3, and either caspase-8 or FADD survived weaning and matured normally. RIPK1 functions in vitro to limit caspase-8-dependent, TNFR-induced apoptosis, and animals lacking RIPK1, RIPK3, and TNFR1 survive to adulthood. The role of RIPK3 in promoting lethality in ripk1 À/À mice suggests that RIPK3 activation is inhibited by RIPK1 postbirth. Whereas TNFR-induced RIPK3-dependent necroptosis requires RIPK1, cells lacking RIPK1 were sensitized to necroptosis triggered by poly I:C or interferons. Disruption of TLR (TRIF) or type I interferon (IFNAR) signaling delayed lethality in ripk1 À/À tnfr1 À/À mice. These results clarify the complex roles for RIPK1 in postnatal life and provide insights into the regulation of FADD-caspase-8 and RIPK3-MLKL signaling by RIPK1.
INTRODUCTION
RIPK1 is a kinase with several roles in signaling by TNFR1 (Biton and Ashkenazi, 2011; Cusson et al., 2002; Kelliher et al., 1998; Vandenabeele et al., 2010; Zhang et al., 2000) , Toll-like receptors (TLRs) (Festjens et al., 2007; Kaiser et al., 2013; Meylan et al., 2004) , interferons (Meylan et al., 2004; Thapa et al., 2013) , the RIG-I-MAVS pathway (Rajput et al., 2011) , and production of IL1a in SHP1-deficient animals (Lukens et al., 2013) . Upon activation, it associates with RIPK3 to form a b-amyloid (Li et al., 2012) , promoting necroptosis and inflammatory cytokine production, dependent on the pseudokinase, MLKL (Kang et al., 2013; Murphy et al., 2013) . In its kinase-active form, it also recruits the adaptor molecule, FADD, which in turn activates caspase-8 to promote apoptosis induced by TLR signaling or DNA damage (Tenev et al., 2011; Wang et al., 2008) . These activities of RIPK1 are effectively blocked by necrostatins, including necrostatin-1 (Nec1) (Degterev et al., 2008) , which act to inhibit the kinase function. Independent of its kinase activity, RIPK1 appears to participate in NF-kB activation through the recruitment of NEMO (Micheau et al., 2001; Wang et al., 2008; Zhang et al., 2000) , although its requirement for NF-kB activation in response to TNFR1 ligation is controversial (Wong et al., 2010) . Nevertheless, the activation of NF-kB induces the expression of c-FLIP L (FLIP), a caspase-like molecule that forms a heterodimer with caspase-8 on FADD and blocks FADD-caspase-8-mediated apoptosis (Micheau et al., 2001; Wang et al., 2008) .
The FADD-caspase-8-FLIP complex functions to inhibit RIPK3 activation, blocking necroptosis. Indeed, early embryonic lethality of fadd À/À or casp8 À/À animals is rescued by ablation of ripk3 (Dillon et al., 2012; Kaiser et al., 2011; Oberst et al., 2011) , and a similar lethality of FLIP-deficient (cflar À/À ) mice is rescued by ablation of both fadd and ripk3 (Dillon et al., 2012) . Together, these findings provided what appeared to be a complete picture of the interactions of FADD-caspase-8-FLIP and the RIPK1-RIPK3-MLKL complexes in the control of cell death .
A fundamental paradox emerged, however, when the function of RIPK1 was interrogated by genetic approaches. Although the embryonic lethality of fadd À/À mice was rescued by ablation of ripk1, these animals died around postnatal day 1 (Zhang et al., 2011) , as had been observed for ripk1
mice (Kelliher et al., 1998) . But if RIPK1 were required for the activation of RIPK3, as discussed above, then fadd
animals should have survived to adulthood, as do fadd (Dillon et al., 2012) . The postnatal lethality of ripk1 À/À animals was therefore most easily explained as being due to the loss of another function of RIPK1 that is a requisite for postnatal survival. For example, RIPK1 has been suggested to regulate the induction of NF-kB by recruitment of NEMO (Zhang et al., 2000) . Perturbation of the NF-kB pathway by ablation of RIPK1 might then trigger the noncanonical NFkB2, as is also observed upon deletion of other elements of the canonical NF-kB pathway (Varfolomeev et al., 2007; Vince et al., 2007; Gentle et al., 2011 ).
An alternative to this explanation, however, is that RIPK1 functions to inhibit both FADD-caspase-8-mediated apoptosis and RIPK3-mediated necroptosis, both triggered by signals generated around the time of birth. This idea stands in striking contrast to the widespread notion that RIPK1, in its kinase-active form, initiates both FADD-caspase-8 mediated apoptosis (Feoktistova et al., 2011; Tenev et al., 2011) and RIPK3 activation to cause necroptosis (Cho et al., 2009; Holler et al., 2000) . However, both caspase-8 and RIPK3 (Kaiser et al., 2013; Moujalled et al., 2013; Upton et al., 2012) can be activated in the absence of RIPK1 in some settings, resulting in different forms of cell death. If RIPK1 can block cell death in these settings, then this might explain why its ablation leads to lethality. Here, we test these ideas by several approaches.
RESULTS

Perinatal Lethality of ripk1
À/À Mice Is Dependent on
Caspase-8 and RIPK3
To test the possibility that perinatal lethality in the ripk1
mouse is due to overactivation of NF-kB2, we generated mice lacking both RIPK1 and the NF-kB2-activator, NIK. Like RIPK1, NIK is regulated by c-IAP1 and c-IAP2 (Varfolomeev et al., 2007; Vince et al., 2007) . Further, TRAF2 or TRAF3 ablation cause perinatal lethality that is prevented on a background 
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(E) 5-week-old ripk1 lacking NIK (Vallabhapurapu et al., 2008) . Nevertheless, we found that ripk1 À/À nik À/À mice did not display any improved survival versus animals lacking RIPK1 alone, and no animals survived to weaning (Figure S1A available online). Therefore, the perinatal lethality caused by loss of RIPK1 is not due to enhanced activity of NIK.
We therefore tested the notion that RIPK1 functions to inhibit two modes of cell death, such that ablation of this protein results in lethality. Although we found that postnatal lethality of ripk1 À/À mice was, at best, only marginally affected by ablation of ripk3 (Figures 1A, S1B, and S1C) and unaffected by ablation of casp8 ( Figures 1A, S1D , and S1E), animals lacking ripk1, ripk3, and casp8 survived into adulthood ( Figure 1A , S1F, and S1G) and were weaned at Mendelian frequencies ( Figure 1B ). Similarly, whereas fadd
À/À mice do not survive the first days of postnatal life (Zhang et al., 2011) , mice lacking ripk1, ripk3, and fadd were weaned at expected frequencies (Figure 1C) .
fadd À/À mice gained weight over time and appeared similar to their littermates for several months ( Figures 1D-1G ). Formally, then, the ripk1 gene inhibits perinatal lethality dependent on ripk3 and either casp8 or fadd. Ripk3
À/À mice eventually display acute lymphoproliferative syndrome (ALPS), normally associated with defects in CD95 signaling (Kaiser et al., 2011; Oberst et al., 2011) . Similarly, ripk1
and 1E) and displayed ALPS after several months ( Figure 2A ), with expansion of the CD3 + B220 + lymphocyte subset associated with ALPS (Bidè re et al., 2006) ( Figures 2B and 2C) . ALPS was also observed in ripk3 À/À fadd À/À mice (Dillon et al., 2012) , and the expansion of the aberrant lymphocyte subset was similarly seen in ripk1 Figure 2D ). Naive T cells from young ripk1
À/À animals were present in normal proportions ( Figure 2E ) and were activated similarly to WT T cells in response to CD3, CD28 ligation (Figure 2F) . Therefore, RIPK1 is not required for in vitro T cell activation or for the expansion of lymphocytes in ALPS. 
The role of caspase-8 in the postnatal lethality of ripk1
À/À animals suggests that RIPK1 functions to inhibit caspase-8-mediated apoptosis in some settings ( Figure 3A) . Indeed, RIPK1-deficient primary MEF were strikingly sensitized to apoptosis induced by treatment with TNF plus low-dose cycloheximide (CHX), showing cleavage of caspase-3, and this cell death was blocked by the caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp (O-Me) fluoromethyl ketone (zVAD) (Figures 3B, S2A, and S2B) . This is consistent with earlier observations that ripk1 À/À -primary MEF are sensitized for cell death induced by TNF plus CHX (Kelliher et al., 1998) . Similarly, ripk1 Figure S2 .
sensitized to TNF plus CHX-induced apoptosis ( Figures 3B, S2A , and S2B). Thus, the loss of RIPK1 sensitized cells to TNF-induced, caspase-8-dependent apoptosis. This is likely due to defects in expression of FLIP, as primary ripk1 À/À MEF showed reduced basal levels of FLIP mRNA as compared to WT MEF ( Figure 3C ) and did not upregulate FLIP mRNA levels upon exposure to TNF ( Figure 3D ). In contrast, we observed no alterations in expression of three other regulators of TNFR1 signaling: c-IAP1, c-IAP2, and X-IAP (Figure S2C) . Similarly, we observed that endogenous, constitutive expression of FLIP in spleen and lung was reduced in animals lacking RIPK1 (Figures 3E and 3F) . FLIP levels are well known to regulate sensitivity to TNF-induced apoptosis (Budd et al., 2006; Micheau et al., 2001; Wittkopf et al., 2013) . FLIP is also required (in the form of the FADD-FLIP-caspase-8 complex) for inhibition of necroptosis induced by TNF , and thus, animals with low FLIP expression due to loss of RIPK1 may be sensitized to necroptosis. However, RIPK1 is required for TNF-induced necroptosis (Vandenabeele et al., 2010) , as we observed in response to TNF plus zVAD, which triggered caspase-3-independent cell death in WT, but not in primary ripk1 À/À MEF ( Figure 3B ).
We therefore investigated the role of TNF in the postnatal lethality of ripk1 À/À ripk3 À/À mice. Although ablation of tnfr1 in ripk1 À/À mice delays but does not rescue postnatal lethality (Cusson et al., 2002) ( Figure S3A ), we observed that ripk1
À/À mice survived weaning into adulthood at Mendelian frequencies ( Figures 4A-4C ). Although these mice initially matured normally and did not manifest ALPS ( Figure S3B ), we noted mortality with time ( Figure 4A ), and this was associated with blood bacteremia ( Figure S3C ), decreased blood lymphocyte, and increased blood neutrophil levels ( Figure S3D ), consistent with sepsis. Even shortly after weaning (P25), intestinal morphology was disrupted with associated apoptosis (Figure S3E) , suggesting that a breakdown in barrier function eventually contributes to mortality in animals lacking tnfr1, ripk1, and ripk3. Nevertheless, ablation of tnfr1 clearly rescues perinatal lethality in ripk1
Our results show that ablation of casp8, fadd, or tnfr1 can prevent perinatal lethality in ripk1
À/À mice. Based on our in vitro studies, it is likely that one RIPK1 function is to sustain postnatal development by inhibiting TNFR1-induced, FADDcaspase-8-dependent apoptosis in one or more critical tissues. Indeed, we observed cell death accompanied by cleaved caspase-3 staining in the intestines, spleens, and lungs of ripk1
. Consistent with our in vitro studies, we observed that the expression of FLIP was decreased in ripk1
À/À spleen and lung, as compared to WT (Figures 3E and 3F) (expression in intestine was too low to detect; data not shown). Previous studies (Kelliher et al., 1998) suggested that ripk1 À/À mice show defects in not only these tissues, but also in thymus and brown fat. Although we did not observe extensive thymocyte cell death in either ripk1 À/À or ripk1
À/À mice (data not shown), both brown and white fat in ripk1 À/À ripk3 À/À mice showed a marked depletion of lipid stores, without overt apoptosis (Figures S3F and S3G) , suggesting that these animals were energetically compromised.
TNFR1-Induced RIPK1 Activity Causes E10.5 Lethality in caspase-8-Deficient Mice We observed that ablation of RIPK1 rescues the embryonic lethality of casp8 À/À mice (Figures 1A and S1D), consistent with the similar rescue of embryonic lethality in fadd À/À mice on the ripk1 À/À background (Zhang et al., 2011) . Thus, although deletion of caspase-8 or fadd alone did not rescue the perinatal lethality seen in ripk1 À/À mice, the embryonic lethality in fadd-or caspase-8-deficient animals is dependent on RIPK1. Because TNF-induced necroptosis in the absence of FADD-caspase-8-FLIP activity is dependent on RIPK1 (Vandenabeele et al., 2010 and Figure 3B ), we asked whether TNFR1 signaling might contribute to the E10.5 embryonic lethality in caspase-8-or fadd-deficient mice. Although casp8
survive to birth, we observed that these animals progressed well beyond E10.5 in development ( Figures 5A-5C ), as the fadd À/À tnfr1 À/À embryos also did ( Figure 5H ). The E10.5 lethality in casp8 À/À mice is associated with a failure to vascularize the yolk sac (Sakamaki et al., 2002) ; however, casp8
mice showed normal vascular development ( Figure 5D ). Similarly, animals lacking FLIP (cflar À/À ) (Yeh et al., 2000) or FLIP and RIPK3 (Dillon et al., 2012 ) die at E10.5, again with a failure to vascularize the yolk sac (Dillon et al., 2012) . As seen in casp8 4A , S1D, and S3A). This suggests that a second signal, besides TNFR1, must engage RIPK3 to promote lethality in the absence of RIPK1 ( Figure 6A ). In addition, in vitro evidence suggests that the signal that engages RIPK3 cannot be via TNFR1. Primary WT MEF underwent caspase-independent necrosis in response to TNF plus zVAD, which was inhibited by the RIPK1 inhibitor, Nec1 ( Figure 3B ), as expected Vandenabeele et al., 2010) , and was absent in treated ripk1 À/À MEF (Figure 3B) . Therefore, TNF-mediated necroptosis requires RIPK1, as previously described (Vandenabeele et al., 2010) , as seen with other death ligands (Holler et al., 2000) . However, our genetic results strongly indicated not only that lethal RIPK3 signaling can proceed independently of RIPK1, but that RIPK1 functions to inhibit this signaling in a critical postnatal setting ( Figure 6A ). We therefore sought a second signal for RIPK3 activation that is exacerbated by ablation of RIPK1. The DNA-dependent activator of interferon regulatory factors, DAI, can directly engage RIPK3 to promote necroptosis independently of RIPK1, but the presence or absence of RIPK1 does not affect this interaction (Upton et al., 2012) . In contrast, poly I:C signaling via TLR3 and TRIF may promote necroptosis that is exacerbated by silencing RIPK1 (Kaiser et al., 2013) . We therefore generated ripk1
animals survived until weaning, we observed a significant delay in mortality as compared to ripk1 Figure 6B ). Therefore, signaling via TRIF may serve as one relevant ''signal 2'' to trigger RIPK3-dependent lethality in the absence of RIPK1 ( Figure 6A ). We then asked whether TRIF could engage RIPK3 in the absence of RIPK1. We stably expressed Fv2-TRIF-HA (a modification of an FKBP domain allowing dimerization upon addition of the rapalog, AP-20187 [AP-1] [Amara et al., 1997] ) in 3T3-SA cells. Addition of dimerizer induced robust cell death only upon addition of zVAD or upon silencing of RIPK1 (without a requirement for zVAD) ( Figure 6C ). Pull-down of TRIF optimally coimmunoprecipitated RIPK1, RIPK3, and MLKL in control cells only in the presence of AP-1 and zVAD ( Figure 6D ). In contrast, in cells with silenced RIPK1, AP1 treatment was sufficient to pull down RIPK3 and MLKL, without a requirement for zVAD ( Figure 6D ). Thus, TRIF can bind RIPK3 independently of RIPK1, and in the See also Figure S3 .
presence of RIPK1, caspase-8 activity (Kaiser et al., 2013) antagonizes RIPK3 function in necroptosis. Consistent with these observations, we saw that poly I:C treatment of WT immortalized MEF-induced cell death only upon addition of zVAD or upon silencing of RIPK1, without a requirement for zVAD ( Figures S4A and S4B) . Silencing of caspase-8 similarly sensitized primary MEF to poly I:C, as described (Kaiser et al., 2013) (Figure S4C ). Nec1 inhibited cell death induced by poly I:C plus zVAD, but only in the presence of RIPK1 ( Figures  S4A and S4B) . We then employed immortalized mlkl À/À MEF, stably expressing an inducible FLAG-tagged MLKL to further interrogate these effects ( Figures 6E-6H ). Addition of zVAD plus poly I:C induced cell death in cells expressing C-terminal, but not N-terminal, tagged MLKL, and this death was inhibited by Nec1 ( Figures 6E and 6F ). Both tagged forms of MLKL coprecipitated RIPK1 and RIPK3 under these necroptotic conditions, and this association was blocked by Nec1 in both cases (Fig- ure 6G). Upon silencing RIPK1, the cell death response to poly I:C, even in the absence of zVAD, was enhanced, and Nec1 did not prevent this cell death (Figures 6E and 6F) . RIPK3 coprecipitated with MLKL in RIPK1-silenced cells only in response to poly I:C, with no effect of Nec1 ( Figure 6G ). In contrast, in immortalized WT MEF expressing N-terminal tagged MLKL (as well as endogenous MLKL), treatment with TNF plus zVAD induced the association of MLKL, RIPK3, and RIPK1, which was lost upon treatment with Nec-1 or silencing of RIPK1 (Figure S4D ). Nec1 addition only partially reduced the amount of RIPK3 coimmunoprecipitated with RIPK1 but prevented its association with MLKL ( Figure 6H ). The resulting cell death was MLKL dependent, as poly I:C-induced cell death in RIPK1-silenced cells was not observed in mlkl À/À cells ( Figures   S4E and S4F ). Therefore, in contrast to TNF-induced necroptosis, RIPK1 is dispensable for poly I:C-induced necroptosis and can inhibit it either through recruitment of caspase activity (blocked by zVAD) or in its Nec1-inhibited form, independently of caspase activity ( Figure 6A ). Although deletion of TRIF significantly delayed lethality in ripk1
À/À mice, most of these animals did not survive to weaning ( Figure 6B ). TRIF is therefore not the only relevant ''signal 2'' that can engage RIPK3-MLKL interaction, antagonized by RIPK1 ( Figure 6A ). Interferons (IFN) reportedly induce necroptosis (Thapa et al., 2013) and thus might represent such a signal. We therefore generated ripk1
lacking the type I IFN receptor. These animals survived significantly longer than did ripk1 À/À tnfr1 À/À mice (p < 0.0001) or ripk1 À/À ifnar À/À mice (p < 0.0001) ( Figure 7A ). As ifnar À/À mice possess receptors for type II IFN, we compared the effects of IFNb and IFNg on primary MEF in vitro. We observed that primary MEF lacking RIPK1 were sensitized to both type I and type II IFN-induced cell death that required RIPK3, independently of caspase-8 ( Figures 7B-7D , S5A, and S5B). In primary WT MEF, IFNs induced cell death only in the presence of zVAD, and this was inhibited by Nec1 ( Figures 7C and 7D ). In contrast, IFN-induced cell death in RIPK1-deficient cells was unaffected by either zVAD or Nec1 ( Figures 7C and 7D ), although the IFN response, as detected by expression of STAT1 or PKR, was equivalent in WT and ripk1 À/À cells ( Figures S5C and S5D ).
Cell death induced by IFN was not observed in primary MEF lacking MLKL ( Figures 7E, S5E , and S5F) and was blocked by silencing or pharmacologic inhibition of PKR, as described (Thapa et al., 2013) (Figures S5G-S5J ).
Interferon treatment of primary WT or ripk1 À/À MEF promoted similar upregulation of MLKL, but not RIPK3 ( Figures S6A-S6C ), as described (Thapa et al., 2013) , and this upregulation was not observed upon treatment with TNF or poly I:C ( Figures S6D-S6F ). We noted that MLKL levels were consistently lower in ripk1 À/À versus WT in three matched sets of primary MEF ( Figure S6A and data not shown). It is possible that this reflects selection against expression of MLKL in ripk1 À/À MEF, further supporting the idea that RIPK1 functions to prevent MLKLdependent death. The increased expression of MLKL induced by IFNs may contribute to necroptosis, but this alone cannot account for the death observed in ripk1 À/À MEF, as the levels in these cells did not exceed those seen in WT MEF ( Figure S6A ), and the effects were dependent on RIPK3 ( Figures 7B, S5A , and S5B). Although engagement of RIPK3 (and MLKL) promotes necroptosis, which may contribute to the perinatal death of ripk1 À/À mice, the RIPK3-MLKL interaction also promotes inflammatory cytokine production (Kang et al., 2013) . We therefore compared the in vivo cytokine levels in mice injected with lipopolysaccharide (LPS) ( Figure S7 showed reduced cytokine levels. Therefore, it is likely that RIPK1 promotes cytokine production in response to LPS, as observed by others (Lukens et al., 2013) , though this did not appear to depend on the presence of RIPK3 or caspase-8 (except in the case of IL-1b, as described [Gurung et al., 2014] ). Therefore, it is unlikely that a lack of RIPK1, per se, directly promotes RIPK3-MLKL-dependent inflammation, at least via TLR engagement. Rather, in work accompanying this paper in this issue of Cell, RIPK1 appears to inhibit inflammation, as systematic inflammation is found in postnatal ripk1
mice, an effect that is dampened in ripk1 (Rickard et al., 2014) . It is possible, however, that a failure to upregulate key cytokines in response to establishment of the microbiota around birth may contribute to postnatal lethality in ripk1 À/À mice. Although no evidence of bacterial sepsis has been found in these animals (Cusson et al., 2002; Kelliher et al., 1998) , we cannot formally rule out this possibility.
DISCUSSION
The elucidation of the function of a gene from mutant phenotypes and the effects of other mutations on those phenotypes is often confounded by the complexities of the genetic interactions. Our finding that the perinatal lethality of ripk1 À/À mice can be prevented with combinations of additional mutations permits two broad conclusions that are, on the surface, fairly straightforward: (1) RIPK1 functions to prevent perinatal lethality caused by the activity of TNFR1, FADD, and caspase-8 and (2) RIPK1 functions to prevent perinatal lethality caused by the activity of TRIF, IFN, and RIPK3. Thus, these proteins operate in two different cell death pathways (the death receptor pathway of apoptosis and RIPK1-independent necroptosis), and while the genetic evidence alone does not permit us to formally conclude , ripk1
(C) 3T3-SA cells stably expressing 2vFV-TRIF-HA were transfected with either scrambled or RIPK1 siRNA and treated with AP-1 dimerizer (10 nM) in the absence or presence of zVAD (25 mM). See also Figure S4 .
that RIPK1 is required only to prevent both pathways of cell death engaged following birth, the results are highly suggestive of this conclusion. The prevention of perinatal lethality in the ripk1 À/À mouse by ablation of these two cell death pathways was not fully anticipated based on previous studies in vitro or in vivo. Although primary MEF from ripk1 À/À mice display increased sensitivity to TNF-induced apoptosis (Kelliher et al., 1998) , RIPK1 has also been shown to promote FADD-dependent caspase-8 activation in response to TNF (Feoktistova et al., 2011; Oberst et al., 2011; Tenev et al., 2011; Zhang et al., 2011) RIPK3-dependent necroptosis induced by TNF (Degterev et al., 2005) , TLR-ligands (He et al., 2011) , or interferons (Thapa et al., 2013) is effectively blocked by the RIPK1 inhibitor, Nec1, suggesting that RIPK1 functions via its kinase activity to promote RIPK3 activation and necroptosis, an idea supported by structural studies of RIPK1-RIPK3 interactions (Li et al., 2012) . Our results extend the latter conclusion and suggest that, under conditions in which RIPK3 is activated independently of RIPK1 (TRIF, IFNs), RIPK1 inhibits necroptosis by recruiting zVADinhibitable caspase activity, likely by the action of FADD-caspase-8-FLIP . In the absence of caspase activity, Nec1 inhibits necroptosis in a RIPK1-dependent manner, suggesting that the Nec1-bound RIPK1 disrupts RIPK3 function. Indeed, we found that Nec1 inhibits the association of RIPK3 and MLKL induced by the TLR3 ligand, poly I:C, but only in the presence of RIPK1 ( Figures 6G and 6H ). Our in vitro and in vivo evidence show that loss of RIPK1 sensitizes primary cells to both TNFR1-FADD-caspase-8-mediated apoptosis induced by TNF and RIPK3-mediated necroptosis induced by TLR ligation (via TRIF) or interferons. We have previously shown that enforced oligomerization of RIPK3 is sufficient to induce MLKL-dependent necroptosis (Tait et al., 2013) . Therefore, oligomerization of TRIF and thus RIPK3 can promote the activation of the latter independently of RIPK1. When RIPK1 is present, recruited caspase activity prevents this activation and interaction with MLKL. These results are consistent with models of RIPK1 and RIPK3 interaction (Li et al., 2012) . In the case of interferon exposure, we propose that PKR contributes to RIPK1-independent activation of RIPK3, as suggested by others (Thapa et al., 2013) , although the precise mechanisms remain obscure.
In mice lacking both ripk1 and ripk3, perinatal lethality is fully penetrant, although our data show that this is dependent on TNFR1, FADD, and caspase-8. Our models suggest that apoptosis, engaged by the latter, is responsible for this lethality. Indeed, we observed widespread apoptosis in these animals. Although apoptosis is readily detected by histological methods, it is more difficult to detect necroptosis, and therefore we can only speculate at this point that perinatal lethality in ripk1 À/À mice is due to a mixture of apoptotic and necrotic death in the same tissues undergoing apoptosis in the ripk1
mice. Further, because RIPK3-MLKL interactions can produce inflammatory effects, apparently independently of cell death (Kang et al., 2013) , we cannot exclude that such inflammation, rather than cell death, contributes to perinatal lethality in the ripk1 À/À mice, although widespread inflammation was not observed in these animals when originally reported (Kelliher et al., 1998) . Such an effect, however, would be excluded in the case of ripk1
In the latter, we and Rickard et al. observed some delay in perinatal lethality versus ripk1 À/À mice, supporting this idea (Rickard et al., 2014) .
Our data support a model of RIPK1 function in development and postnatal life ( Figure 7F ). Because ablation of RIPK1 sensitizes for both TNFR1-FADD-caspase-8-dependent and RIPK3-dependent lethality, we must assume that these pathways are not engaged prior to birth. FADD-or caspase-8-deficient mice die in utero, and this embryonic lethality is fully prevented upon ablation of RIPK3 (Dillon et al., 2012; Kaiser et al., 2011; Oberst et al., 2011) . However, because RIPK1-deficient animals survive to birth, the signals responsible for such embryonic lethality are not held in check by RIPK1 and, indeed, are promoted by it. Prior to birth, RIPK1 promotes TNFR-mediated lethality at E10.5 in animals lacking fadd, caspase-8, or flip (Zhang et al., 2011 and Figure 5 ) and lethality at a later developmental checkpoint that might be mediated by similar signals, perhaps from other TNFR-related receptors (or another signal with the properties of signal 1). We observed that cells lacking RIPK1 do not undergo necroptosis in response to TNFR ligation, consistent with other observations (Vandenabeele et al., 2010) , supporting the idea that the later-stage lethality seen in casp8
embryos is mediated by a TNFR1-like necroptosis-inducing signal. At the time of birth, RIPK1 is required to prevent a TNFR1-induced FADD-and caspase-8-dependent lethality in ripk1
À/À animals, possibly relating to a failure to upregulate FLIP in response to TNFR1 signaling. If so, FLIP, which is required for development beyond E10.5, must be expressed at that time independently of RIPK1. Postbirth, RIPK1 is also required to prevent RIPK3-dependent lethality promoted by TRIF, IFN, and possibly other signals. It is likely that this inhibition is mediated by the recruitment, via RIPK1, of FADD-caspase-8-FLIP, which does not promote apoptosis but which functions catalytically to inhibit RIPK3 function , directly engaged by these signals.
Mice with a kinase-dead mutation of RIPK1 show normal development and maturation, although cells from these animals appear to be defective in TNF-induced necroptosis (Newton et al., 2014) . The mechanisms by which the kinase activity of RIPK1 either promotes or prevents cell death in other contexts still remain obscure. Strikingly, mice with a kinase-dead mutation of RIPK3 die at E10.5 and were rescued to birth by ablation of RIPK1 or fully rescued by ablation of caspase-8 (Newton et al., 2014) , indicating that RIPK3 can itself engage both RIPK1 and caspase-8. Although it remains unclear why kinase-dead RIPK3 is hyperactive in this regard, the results are consistent with the pathways described; disruption of either the necroptotic pathway (by mutation of the RIPK3 kinase domain) or the apoptotic pathway (by ablation of caspase-8, FADD, or FLIP) ''unbalances'' the system in favor of lethality by the other pathway. Ablation of RIPK1 similarly unbalances these pathways but only after birth, suggesting that the inhibitory function of RIPK1 only becomes essential when additional signals (such as TLR/TRIF and IFN) manifest.
RIPK1 is under complex regulation by a number of ubiquitin ligases and deubiquitinases. cIAP1/2 mediate K63 ubiquitinylation of RIPK1, whereas LUBAC (HOIP, HOIL, sharpin) causes linear ubiquitylation of RIPK1, both of which are involved in recruitment of NEMO (Bertrand et al., 2008; Gerlach et al., 2011) The deubiquitinase CYLD removes the K63-Ub, promoting activity in necroptosis (Moquin et al., 2013) . In contrast, A20 ''edits'' these linkages from K63 to K48 (Wertz et al., 2004) , destabilizing the protein. How these interactions may impact the complex patterns that we observed for the maintenance of perinatal life remain obscure. However, one might expect that intracellular pathogens that disrupt elements of this process at any of a variety of points would trigger cell death, preventing further spread of the pathogen. If so, this may suggest a reason why this complex interrelationship exists and why ablation of specific elements (including RIPK1, FADD, caspase-8, FLIP, and the kinase activity of RIPK3) push the system to lethality. It may also be relevant that the tissues that are most affected by such disruption (intestine, lung, skin, endothelium, hematopoietic cells) (Khan et al., 2014) represent barriers that are potentially engaged by such pathogens.
EXPERIMENTAL PROCEDURES
For further experimental procedures, please see the Extended Experimental Procedures.
Mice, In Vivo Treatments, and Serum Analysis Ripk3 Oberst et al., 2011) , ripk3 Dillon et al., 2012) , Kelliher et al., 1998) , tnfr1 À/À (Pfeffer et al., 1993) , cflar À/À (Yeh et al., 2000) , trif Yamamoto et al., 2003) , and ifnar À/À (Mü ller et al., 1994) mice have been previously described. The mlkl À/À mice were generously provided prior to publication by Warren S. Alexander . The St. Jude Institutional Animal Care and Use Committee approved all procedures in accordance with the Guide for the Care and Use of Animals.
Cell Lines
Primary murine embryonic fibroblasts (MEF) were generated by mating animals of the required genotypes and harvesting embryos at E12-E14 based on palpation. Following removal of the head and fetal liver, a single suspension was generated from the remaining parts of the embryo and plated in DMEM supplemented with 10% FCS, L-glutamine, pen/strep, 55 mM b-mercaptoethanol, 1 mM sodium pyruvate, and nonessential amino acids (GIBCO). All experiments on primary MEF were performed on cells no older than passage 3, and data shown represent experiments using independently derived MEF. Some of the primary MEF were immortalized with SV40 and maintained in DMEM as above except with 5% FCS.
Immune Cell Staining, Cell Death, and Activation Assays For immune cell staining, the spleen, thymus, and lymph node were harvested from animals and disassociated into single-cell suspensions through a filter. For immune cell staining from the blood, blood was harvested from the retroorbital sinus from animals anesthetized with 2%-2.5% isoflurane in oxygen. Red blood cells were lysed in hypotonic buffer, and samples were stained with antibodies as described below. Data were acquired using a FACScan or Fortessa using FlowJo Collectors or FACSDiva software, respectively, whereas data analysis was performed using FlowJo (Tree Star). For cell death assays, cells were treated with the specified compounds and harvested at the indicated time points, stained with propidium iodide (Sigma-Aldrich), and assayed for viability using flow cytometry. In some cell death assays, cells were stained with Annexin V-APC (Invitrogen) in addition to propidium iodide. For cleaved caspase-3 intracellular staining, cells were harvested at the indicated time points, fixed, permeabilized, and stained per manufacturer's instructions (BD Biosciences). Alternatively, cell death analysis was performed using an Incucyte Kinetic Live Cell Imaging system by staining cells with Sytox Green (Life Technologies) and then imaging every 30 min to 1 hr for the length of the experiment. Proliferation assays and culture conditions for T cells were performed per standard protocols as follows: splenic T cells were isolated from whole spleen using magnetic separation (Pan T cell isolation kit II, ). Cells were stained with CFSE and plated at 1 3 10 5 cells per well in 96-well plates with plate-bound anti-CD3 (4 mg/ml) and anti-CD28 (4 mg/ml). Splenocytes were cultured in RPMI 1640 (Invitrogen) supplemented with 10% FCS, L-glutamine, pen/strep, 55 mM b-mercaptoethanol, 1 mM sodium pyruvate, and nonessential amino acids (GIBCO).
Immunoprecipitation of MLKL and TRIF N-and C-terminal FlagM2-tagged mMLKL were cloned into the doxycyclineinducible vector pRetroX-TRE3G (631188; Clontech, CA. USA). WT or mlkl À/À MEF were transduced and selected with 4 mg/ml puromycin according to manufacturer's instructions. In brief, MLKL expression was induced by incubating mlkl À/À MEF with 1 mg/ml DOX for 4 hr for immunoprecipitation and for 10 hr for cell death experiments. During induction, cells were all incubated with 50 mg/ml poly I:C or 10 ng/ml TNF in the presence or absence of 50 mM zVAD and/or 30 mM Nec1. For immunoprecipitation experiments with N-term FLAG-MLKL pull-downs in WT MEF, MLKL expression was induced for 24 hr before treatment with 1 mg/ml DOX. 3T3-SA cells transduced with pMSCV-2Fv-mTRIF-HA-IRES-mCherry were selected by cell sorting. TRIF dimerization was induced using 10 nM AP-20187 homodimerizer in the absence or presence of 25 mM zVAD. Cell lysates were generated using a lysis buffer containing: 50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 0.5% NP-40, and Cocktail Protease Inhibitor (Roche). FLAG immunoprecipitation was performed using anti-FLAG beads according manufacturer instructions (Sigma, F2426). Endogenous immunoprecipitation for RIPK1 was performed by coupling anti-RIPK1 (610458; BD PharMingen) with protein A/G PLUSAgarose (sc-2003; Santa Cruz Biotechnologies). HA immunoprecipitation was performed using anti-HA beads (A2095; Sigma). All eluted immunoprecipitates were boiled, and 5% of input was loaded onto 4%-12% precast gels (Bio-Rad). After transfer, membranes were probed with the specified antibodies. 
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